Completed PHASE4 INTERVENTIONAL 2-arm NCT01950819

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) (TRANSFORM)

A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation

Sponsor: Novartis Pharmaceuticals

Conditions Chronic Kidney Disease (CKD) End Stage Renal Disease (ESRD) Hemodialysis Renal Replacement Therapy Renal Transplantation

Interventions Corticosteroids EVR+rCNI Induction therapy MPA+sCNI

Updated 14 times since 2017 Last updated: Jan 9, 2019 Started: Dec 3, 2013 Primary completion: Feb 1, 2017 Completion: Jan 17, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD) and is currently completed. Novartis Pharmaceuticals leads this study, which shows 14 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

14 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE4
Nov 2025 — Dec 2025 [monthly]

Completed PHASE4
Sep 2025 — Nov 2025 [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4

▶ Show 9 earlier versions

Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Feb 2019 — Jan 2021 [monthly]

Completed PHASE4
Oct 2018 — Feb 2019 [monthly]

Completed PHASE4
Jun 2018 — Oct 2018 [monthly]

Completed PHASE4
Mar 2018 — Jun 2018 [monthly]

Completed PHASE4

Status: Active Not Recruiting → Completed
Dec 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE4
Sep 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE4
Feb 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Al Mansurah, Egypt , Amsterdam, Netherlands , Ann Arbor, United States , Antalya, Turkey (Türkiye) , Athens, Greece , Aurora, United States , Baltimore, United States , Bangalore, India , Bangkok, Thailand and 154 more locations